Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
August 20, 2021
August 20, 2021
1da84f16-4374-4eb9-87cd-f13d1d965346
Related Documents
Data Integrity for In Vivo Bioavailability and Bioequivalence Studies
Guidance DocumentApril 3, 2024Center for Drug Evaluation and Research
Updating ANDA Labeling After the Marketing Application for the Reference Listed Drug Has Been Withdrawn Guidance for Industry
Guidance DocumentJuly 11, 2016Center for Drug Evaluation and Research
Statistical Approaches to Establishing Bioequivalence
Guidance DocumentDecember 2, 2022Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox